Shimadzu Corporation Acquires German Startup Plasmion to Revolutionize Mass Spectrometry
In a strategic move poised to reshape the landscape of analytical science, Shimadzu Corporation, a global leader in scientific instrumentation, has acquired a 75% stake in Plasmion GmbH, a cutting-edge German startup specializing in mass spectrometry innovation. The acquisition, finalized on March 23, 2026, marks a significant step in Shimadzu’s efforts to integrate Plasmion’s proprietary SICRIT (Soft Ionization by Chemical Reaction In Transfer) technology into its next-generation analytical tools. This collaboration promises to unlock new possibilities in healthcare, environmental monitoring, and food science—fields where precision and real-time analysis are critical.
Why SICRIT Technology Is a Game-Changer
Mass spectrometry (MS) has long been a cornerstone of analytical chemistry, enabling scientists to identify and quantify compounds with unparalleled accuracy. Yet, traditional methods like APCI (Atmospheric Pressure Chemical Ionization) often require complex sample preparation, limiting their efficiency in real-time applications. Plasmion’s SICRIT technology addresses this challenge head-on by offering a revolutionary approach to ionization—one that eliminates the need for cumbersome preprocessing while delivering high-sensitivity analysis.
Key advantages of SICRIT include:
- Direct Ionization: Analytes are ionized without extensive sample preparation, streamlining workflows in laboratories and field settings.
- High Sensitivity: Detects trace compounds with exceptional precision, making it ideal for applications like disease biomarker discovery and environmental toxin monitoring.
- Non-Destructive Analysis: Preserves sample integrity, a critical factor in fields like food science, where aroma components must remain unaltered.
“SICRIT isn’t just an incremental improvement—it’s a paradigm shift,” says a spokesperson for Shimadzu. “By integrating this technology into our mass spectrometers, we’re enabling scientists to push the boundaries of what’s possible in real-time analysis.”
Applications Across Industries
The potential applications of SICRIT technology span multiple sectors, each with its own set of transformative possibilities:
Healthcare: Breath Analysis for Early Disease Detection
One of the most promising applications of SICRIT lies in exhaled breath analysis. Researchers have long explored the idea of detecting disease biomarkers in breath—a non-invasive, rapid, and patient-friendly diagnostic method. SICRIT’s high sensitivity makes it uniquely suited for this purpose, potentially enabling early detection of conditions like cancer, diabetes, and respiratory diseases.
“Imagine a world where a simple breath test could diagnose diseases before symptoms even appear,” notes a Shimadzu representative. “That’s the future SICRIT is helping us build.”
Environmental Monitoring: Tracking Hazardous Substances in Real Time
Environmental agencies and industrial facilities rely on mass spectrometry to monitor air and water quality, but traditional methods often fall short in detecting ultra-trace levels of pollutants. SICRIT’s ability to analyze samples without extensive preparation makes it a powerful tool for real-time environmental monitoring, from tracking industrial emissions to identifying microplastics in water sources.
Food and Beverage: Preserving Aroma and Flavor Profiles
In the food and beverage industry, maintaining the integrity of aroma compounds is essential for quality control. Traditional mass spectrometry methods can alter these delicate compounds during analysis, but SICRIT’s non-destructive approach ensures that samples remain unchanged. This opens doors for more accurate flavor profiling, fraud detection, and shelf-life studies.
The Acquisition: A Strategic Partnership
Shimadzu’s acquisition of Plasmion is more than a financial transaction—it’s a strategic alignment of expertise. The two companies have collaborated since 2019, with Shimadzu providing Plasmion access to its mass spectrometry products and technical insights. This partnership has already yielded promising results, and the acquisition is expected to accelerate the development of next-generation analytical tools.
Plasmion’s founders, Dr. Thomas Wolf (CEO) and Dr. Jan-Christoph Wolf (CTO), will retain a 25% stake in the company and continue to play active roles in its management. Their ongoing involvement ensures that Plasmion’s innovative culture and technical prowess remain intact under Shimadzu’s umbrella.
“This acquisition is a testament to the power of collaboration,” says Dr. Thomas Wolf. “By combining Plasmion’s SICRIT technology with Shimadzu’s global reach and resources, we’re poised to redefine what’s possible in mass spectrometry.”
What’s Next for Shimadzu and Plasmion?
With the acquisition complete, Shimadzu is already laying the groundwork for integrating SICRIT into its product lineup. The company plans to develop next-generation mass spectrometers that leverage SICRIT’s capabilities, with a focus on applications in clinical diagnostics, pharmaceutical research, and environmental science.
“Our goal is to develop high-sensitivity, real-time analysis accessible to laboratories worldwide,” says a Shimadzu executive. “This acquisition is a major step toward that vision.”
Key Takeaways
- Shimadzu Corporation has acquired a 75% stake in Plasmion GmbH, a German startup specializing in mass spectrometry innovation.
- Plasmion’s SICRIT technology enables high-sensitivity, real-time analysis without complex sample preparation.
- Applications include healthcare (breath analysis for disease detection), environmental monitoring, and food science.
- Plasmion’s founders will retain a 25% stake and remain involved in the company’s management.
- The acquisition builds on a collaborative relationship dating back to 2019, with plans to integrate SICRIT into Shimadzu’s next-generation mass spectrometers.
FAQ
What is SICRIT technology?
SICRIT (Soft Ionization by Chemical Reaction In Transfer) is a groundbreaking ionization method for mass spectrometry that allows for high-sensitivity analysis without extensive sample preparation. It overcomes many of the limitations of traditional methods like APCI.
How will this acquisition benefit Shimadzu?
The acquisition strengthens Shimadzu’s mass spectrometry portfolio by integrating Plasmion’s innovative SICRIT technology. This will enable Shimadzu to offer next-generation analytical tools with enhanced sensitivity and real-time capabilities.
What industries will benefit from SICRIT technology?
SICRIT has applications across multiple industries, including healthcare (disease biomarker detection), environmental monitoring (pollutant tracking), and food science (aroma and flavor analysis).
Will Plasmion continue to operate independently?
While Plasmion is now a subsidiary of Shimadzu, its founders will retain a 25% stake and remain actively involved in the company’s management. This ensures continuity in Plasmion’s innovative culture and technical development.
The Future of Mass Spectrometry
Shimadzu’s acquisition of Plasmion is more than a corporate milestone—it’s a glimpse into the future of analytical science. As SICRIT technology becomes integrated into mainstream mass spectrometry, we can expect breakthroughs in disease detection, environmental protection, and food safety. For scientists, researchers, and industries that rely on precise, real-time data, this partnership is a beacon of innovation, signaling a new era of possibilities.
Stay tuned as Shimadzu and Plasmion perform together to turn these possibilities into reality.